Background: Recent studies suggest an increased frequency of peripheral neuropathy (PN) in Parkinson's disease patients (PD) (Toth et al. 2010). The aim of our study is to verify the increased frequency of PN in our group of PD patients compared to an age-matched control group. We sorted patients according to the duration of L-DOPA treatment, L-DOPA dosage, and age below or over 50 years.
Methods And Results: We conducted electromyography examinations (using conduction studies and needle electromyography) of 49 PD patients with asymptomatic polyneuropathy and 40 controls. Patients without risk factors for PN were included (fasting blood was analyzed to rule out possible causes of PN), as were relatively healthy controls without risk factors for PN. PN was defined using the American Academy of Neurology and Electrodiagnostic Medicine criteria (England et al. 2005).
Conclusion: The frequency of polyneuropathy was significantly higher in PD patients than in controls (45% versus 2%, p<0.0001). We did not establish a relationship in the PD group according to long-term L-DOPA usage, PD duration, or age. It should be assumed that a neurodegenerative process underlies the involvement of the central and peripheral nervous systems in PD patients.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Comparing autonomic nervous system function in patients with functional somatic syndromes, stress-related syndromes and healthy controls.
J Psychosom Res
December 2024
REVAL - Rehabilitation Research Center, Faculty of Rehabilitation Sciences, Hasselt University, Diepenbeek, Belgium; Health Psychology, Faculty of Psychology and Educational Sciences, KU Leuven, Leuven, Belgium. Electronic address:
Background: The goal of this study was to examine autonomic nervous system function by measuring heart rate (HR), heart rate variability (HRV), skin conductance levels (SCL), and peripheral skin temperature (ST) in response to and during recovery from psychosocial stressors in patients with functional somatic syndromes (FSS; fibromyalgia and/or chronic fatigue syndrome), stress-related syndromes (SRS; overstrain or burn-out), and healthy controls (HC).
Methods: Patients with FSS (n = 26), patients with SRS (n = 59), and HC (n = 30) went through a standardized psychosocial stress test consisting of a resting phase (120 s), the STROOP color word task (120 s), a mental arithmetic task (120 s) and a stress talk (120 s), each followed by a 120 s recovery period. HR, HRV, SCL, and ST were monitored continuously.
Exploring The Therapeutic Potential of Natural Plants in Modulating Molecular and Cellular Pathways Involved in Diabetic Neuropathy: Mechanism and Biochemical Evaluation.
Curr Pharm Des
January 2025
Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.
Diabetic Neuropathy (DN) is a widespread and severely debilitating consequence of diabetes mellitus that impairs function, causes discomfort, and damages peripheral nerves. Numerous molecular pathways are involved in the pathogenesis of DN, including cyclooxygenase, polyol, protein kinase C, and inflammatory pathways. These molecular pathways may be responsible for the mechanism behind the onset and development of DN.
View Article and Find Full Text PDFNovel therapeutic approaches targeting 5-HT7 receptors outside the central nervous system.
J Recept Signal Transduct Res
January 2025
Department of Pharmacology, Faculty of Medicine, Ataturk University, Erzurum, Turkey.
Serotonin (5-HT) is a neurotransmitter found throughout the human body that regulates many physiological events arising from the brain and central nervous system (CNS), such as sleep and appetite. However, it has many other functions in systems outside. In addition to the routine expression of 5-HT7 receptors in CNS regions, such as the pituitary gland, spinal cord, and hippocampus, many studies have reported the expression of these receptors in pathological conditions outside.
View Article and Find Full Text PDFCerebellar Ataxia, Neuropathy, and Vestibular Areflexia as a Presentation of a Novel DNMT1 Mutation.
Cerebellum
January 2025
Department of Neurology, Division of Neuro-Visual & Vestibular Disorders, The Johns Hopkins University School of Medicine, Johns Hopkins Hospital, 600 N. Wolfe Street, Baltimore, MD, USA.
A 50-year-old woman with a 20-year history of gait instability presented with new-onset vertigo and oscillopsia. Examination revealed bilateral vestibular loss, cerebellar ataxia, sensory neuropathy, a "yes-yes" head tremor, nystagmus and a family history of a similar syndrome. Genetic testing for cerebellar ataxia with neuropathy and bilateral vestibular areflexia syndrome (RFC1) was negative, but whole exome sequencing identified a novel mutation in the DNA methyltransferase 1 (DNMT1) gene, broadening the differential diagnosis for this phenotype.
View Article and Find Full Text PDFKaempferol attenuates experimental autoimmune neuritis through TNFR1/JNK/p38 signaling pathway inhibition.
Int Immunopharmacol
January 2025
Institute of Medical Sciences, General Hospital of Ningxia Medical University, Yinchuan 750004, China; Diagnosis and Treatment Engineering Technology Research Center of Nervous System Diseases of Ningxia, Yinchuan 750004, China; Neurology Center, General Hospital of Ningxia Medical University, Yinchuan 750004, China. Electronic address:
Kaempferol (Kae) is a flavonoid that has antioxidant, anti-inflammatory and neuroprotective effects. In recent years, there have been increasing reports on viral infection-induced Guillain-Barré syndrome (GBS) with high rates of disability and fatality. Therefore, in order to search for effective peripheral nerve injury repair drugs, we used rats with experimental autoimmune neuritis (EAN) as the typical animal model for GBS, and implemented Kae treatment intervention on EAN rats.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!